Respiratory and Meningeal Pathogens Research Unit, Medical Research Council, University of Witwatersrand, Johannesburg, South Africa.
Vaccine. 2011 Apr 18;29(18):3372-3. doi: 10.1016/j.vaccine.2011.02.089. Epub 2011 Mar 9.
Protection against serotype 1 could not be demonstrated in two randomized trials of 9 valent pneumococcal conjugate vaccines. An analysis of the timing of type 1 cases among vaccinees and controls shows that the vaccine failures occurred among cases occurring after the first year of life. Vaccination was given as three doses in infancy with no booster dose. These data suggest that a booster dose given at 9 months of age, or early in the second year of life, should be evaluated for protection against type 1 pneumococcal disease.
在两项针对 9 价肺炎球菌结合疫苗的随机试验中，均未能证明对 1 型血清型具有保护作用。对疫苗接种者和对照组中 1 型病例发生时间的分析表明，疫苗接种失败发生在 1 岁以后的病例中。疫苗接种是在婴儿期接种 3 剂，没有加强剂。这些数据表明，应评估在 9 个月龄或 2 岁龄早期给予加强剂以预防 1 型肺炎球菌疾病。
